Fintel reports that on March 4, 2025, Leerink Partners downgraded their outlook for Lexicon Pharmaceuticals (NasdaqGS:LXRX) ...

Lexicon Pharmaceuticals shares are trading lower by 48% Monday morning. The company earlier announced topline results from ...

Leerink analyst Roanna Ruiz downgraded Lexicon (LXRX) to Market Perform from Outperform with a price target of $1, down from $2. The “modest” ...

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Lexicon Pharmaceuticals (LXRX – Research Report) today and set a price ...

Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They ...

Lexicon Pharmaceuticals, Inc. LXRX announced that the FDA plans to hold an advisory panel meeting to give a recommendation on ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

Conference call and webcast at 8:00 a.m. ET on Monday, March 3, 2025THE WOODLANDS, Texas, March 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the ...

There is no Morningstar’s Analysis data available. We sell different types of products and services to both investment professionals and individual investors. These products and services are ...